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Abstract
Background: Ovarian cancer is a silent and largely asymptomatic cancer, leading to late diagnosis and worse
prognosis. The late-stage detection and low survival rates, makes the study of the space-time evolution of ovarian
cancer particularly relevant. In addition, research of this cancer in small areas (like provinces or counties) is still scarce.
Methods: The study presented here covers all ovarian cancer deaths for women over 50 years of age in the provinces
of Spain during the period 1989-2015. Spatio-temporal models have been fitted to smooth ovarian cancer mortality
rates in age groups [50,60), [60,70), [70,80), and [80,+), borrowing information from spatial and temporal neighbours.
Model fitting and inference has been carried out using the Integrated Nested Laplace Approximation (INLA) technique.
Results: Large differences in ovarian cancer mortality among the age groups have been found, with higher mortality
rates in the older age groups. Striking differences are observed between northern and southern Spain. The global
temporal trends (by age group) reveal that the evolution of ovarian cancer over the whole of Spain has remained
nearly constant since the early 2000s.
Conclusion: Differences in ovarian cancer mortality exist among the Spanish provinces, years, and age groups. As the
exact causes of ovarian cancer remain unknown, spatio-temporal analyses by age groups are essential to discover
inequalities in ovarian cancer mortality. Women over 60 years of age should be the focus of follow-up studies as the
mortality rates remain constant since 2002. High-mortality provinces should also be monitored to look for specific risk
factors.
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Background
The number and scientific impact of publications on ovar-
ian cancer are continuously increasing [1]. Not in vain,
ovarian cancer is the eighth most common cancer in
women and the 18th most frequent overall, with nearly
300,000 new cases worldwide in 2018 [2]. Around 50%
of cases are concentrated in developed countries, where
ovarian cancer is the most lethal gynecological tumor.
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The highest incidences are found in northern and eastern
Europe (Austria, the Czech Republic, Germany, Ireland,
Latvia, Lithuania, the Nordic countries, Slovakia, and the
UK) and the United States [3], whereas in Africa and
Asia this tumor is virtually non-existent. This pattern is
attributedmostly to the low birth rates found in developed
countries [4].
In the past 20 years, the overall number of tumors has
undergone a constant increase in Spain. This is due not
only to the population growth, but also to the increased
life expectancy and the use of early detection techniques.
In 2017, the estimated number of new cases of ovarian
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cancer was 3142, representing 5.1% of all female cancers,
being the fifth cause of cancer deaths in women after
lung, breast, colon, and uterine tumors [5, 6]. The age-
standardized incidence rate, calculated using the direct
method and the world standard population, is 7.4 per
100,000 women, which may be considered high. As for
its temporal evolution, there was a slight decline between
1997 and 2003, but since then, mortality rate starts to
increase slowly, but constantly. In addition, there is a great
deal of variability among the Spanish provinces; for exam-
ple, during the period 2003–2007, one finds a rate of 6.7
per 100,000 women in the Canary Islands and a rate of
10.0 per 100,000 women in Cuenca [7].
Ovarian cancer is a disease affecting mostly older post-
menopausal women, with more than 80% of cases being
diagnosed in women over 50 [8]. According to medical
experts, it is a silent and mostly asymptomatic cancer, a
circumstance that leads to late diagnosis and worse prog-
nosis [9]. Furthermore, in the cases where symptoms do
appear, these may be confused with digestive problems
(bloating, early satiety, abdominal and/or pelvic pain) or
benign gynecological alterations such as endometriosis or
polycystic ovary syndrome. To date, no method for early
detection is available. This is reflected in the fact that up
to 75% of cases are detected in the advanced stages of the
disease [5].
The etiology of ovarian cancer is poorly understood.
However, several factors associated with an increased risk
of ovarian cancer have been identified: age, number of
ovulations (early menarche, infertility, low parity), the
use of hormone replacement therapy (HRT) [10], obe-
sity, physical inactivity, a family history of breast and
ovarian cancer, including BRCA1 and BRCA2 gene muta-
tions [11], and past and current smoking [12]. Associa-
tions between exposure to asbestos in the workplace or
at home and ovarian cancer have also been found [13].
Further research is needed to corroborate this finding in
Spain as most jobs with a high exposure to asbestos are
predominantly male-dominated, e.g. mining, milling or
shipyard work. Nevertheless, a study of asbestos expo-
sure among Italian women [14] found that the main factor
was second-hand contact due to occupationally exposed
relatives, for example from soiled work clothes brought
home. As of this writing, however, there is no docu-
mented registry for asbestos exposure in the workplace
or at home in Spain. Some epidemiological studies have
detected an increased risk of ovarian cancer in women
with less exposure to sunlight and consequently with low
levels of vitamin D. In particular, the higher the latitude,
the less overall accumulated sunlight, and the higher the
incidence of ovarian cancer [15]. Some protective fac-
tors against ovarian cancer have also been identified such
as multiparity, oral contraceptives, and tubal ligation or
hysterectomy [16].
The 5-year age-standardised relative survival in Spain
(2000-2007) is estimated at less than 36.8%, similar to
the European average of 37.6% [17]. As mentioned above,
ovarian tumors are the eighth cause of cancer deaths
among women worldwide, with 125,000 deceases regis-
tered in 2002 (4.3% overall among malign tumors) [17]. In
2016, about 1,960 women died yearly in Spain from ovar-
ian cancer, representing 4.4% of all cancer deaths and 1.7%
of all deaths among women [18].
The mean age of decease from ovarian cancer in
Spain is 67.7 years. Cabanes et al. (2009) [19] analyzed
the age-adjusted mortality trends of ovarian cancer in
Spain for the period 1980–2006. Ovarian cancer caused
36,157 deaths in this period, with rates in women over
50 showing a ten-fold increase versus those in younger
women. In women under 50, rates increased 1.6% per
year until 1995, and afterwards started to drop at a rate
of −1.4% per year. In the age group 50–64, mortality
rates significantly increased 4.4% annually up to 1998 and
became stable thereafter. In women 65 and older, mortal-
ity rates increased 5.8% annually up to the year 2000, and
decreased 2.0% per year after.
The disproportionate impact on older women, together
with the aforementioned concerns regarding late-stage
detection and low survival rates, makes the study of the
space-time evolution of ovarian cancer particularly rel-
evant. In addition, it is important to mention that age
groups are not equally affected by ovarian cancer mortal-
ity, and then, it is necessary not just to standardize by age,
but to analyze the different age groups. Hence, the main
goal in this paper is to study the temporal evolution of the
geographical patterns of ovarian cancer mortality rates in
four age groups of women aged 50 years or more.
Methods
Data source
The study presented here covers all ovarian cancer deaths
(code C56 of the 10th edition of the International Classi-
fication of Diseases [20]) for women over 50 years of age
in the 50 provinces of Spain (excluding the autonomous
cities of Ceuta and Melilla), recorded throughout the
period 1989–2015 by the Spanish Statistical Office.
Statistical analysis
A Bayesian hierarchical spatio-temporal model is used to
estimate rates [21]. The model is briefly described in what
follows for better interpretation of results.
Spain is divided into S = 50 provinces indexed by i =
1, . . . , S, and data are available for T=27 time periods (cor-
responding to years 1989–2015) labeled as t = 1, . . . ,T .
For each age group, letNit represent the population at risk
for region i and time period t. Then, conditional on the
mortality rates rit , the number of ovarian cancer deaths
Oit is assumed to follow a Poisson distribution with mean
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Table 1 Descriptive statistics of observed cases and crude mortality rates per 100,000 women disaggregated by age groups, province,
and year. Min: minimum; Q1: first quartile; Q3: third quartile; Max: maximum
Age group Min Q1 Median Mean Q3 Max
Observed cases [ 50, 60) 0.00 2.00 5.00 7.00 8.00 63.00
[ 60, 70) 0.00 3.00 5.00 9.20 10.00 79.00
[ 70, 80) 0.00 3.00 6.00 9.10 11.00 81.00
[ 80,+) 0.00 1.00 2.00 3.80 5.00 49.00
Crude rates [ 50, 60) 0.00 10.17 14.73 15.38 19.44 65.46
[ 60, 70) 0.00 15.80 21.84 22.61 28.48 93.25
[ 70, 80) 0.00 20.91 30.46 30.66 39.49 139.39
[ 80,+) 0.00 15.83 30.96 32.27 46.25 158.38
μit = Nitrit , that is,
Oit|rit ∼ Poisson(μit = Nitrit)
logμit = logNit + log rit ,
where the log-rate is modelled as
log rit = α + ξi + γt + δit . (1)
Here, α denotes the logarithm of the overall rate, ξi and
γt are the main spatial and temporal effects respectively,
and δit corresponds to the space-time interaction effects.
Since each of these components are supposed to be Gaus-
sian Markov random fields (GMRF) [22], the integrated
nested Laplace approximation (INLA)[23] technique has
been used for model fitting and inference. Specifically, the
Leroux et al. [24] CAR prior distribution has been con-
sidered for the spatial random effects and a first-order
random walk prior distribution for the temporal random
effects. In addition, the four different types of interaction
introduced by Knorr-Held [25] have been considered for
the spatio-temporal random effects. These interactions
allow the space-time effects to be completely independent
(Type I interaction), structured in time but not in space
(Type II interaction), structured in space but not in time
(Type III interaction), or completely structured in space
and time (Type IV interaction).
All the computations have been done using the inter-
active web application SSTCDapp [26], which can be
found at https://emi-sstcdapp.unavarra.es/Login/. This
application provides a user interface for the analysis of
spatio-temporal areal count data allowing to fit a wide
variety of space-time models using the INLA estimation
technique. In addition, the application provides different


































Fig. 1 Temporal trends by age groups. Temporal trend of the ovarian cancer mortality (crude) rates by age-groups
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lowest value of the Deviance Information Criterion (DIC)
[27] has been selected. For further details about model
specification, prior distribution of the hyperparameters,
identifiability constraints, and additional model selection
criteria see for example Adin et al. [26] and the references
therein.
Results
A total of 28,350 ovarian cancer deaths were registered in
the population of Spanish women over 50 years of age dur-
ing the period 1989–2015. Since ovarian cancer is mainly
related to the onset of menopause, the age groups we are
considering in this paper are [ 50, 60), [ 60, 70), [ 70, 80),
and [ 80,+). A brief summary of observed cases and mor-
tality rates (per 100,000 women) by age groups, province
and year is shown in Table 1. Clear differences are
observed in the mean and median mortality rates among
the youngest and oldest age groups, with values rang-
ing from 15 cases per 100,000 women up to 32 cases
per 100,000 women (approximately) respectively. Figure 1
displays the global temporal trend of crude rates by age
group. Here the different behaviour of the age groups is
even more evident. A pronounced slope from the last
decade of the twentieth century to the beginning of the
twenty-first century is observed in the older age groups.
Model (1) was fitted to smooth spatio-temporal rates in
each age group. The interaction considered in the model
was chosen on the basis of the DIC values for each sub-
group of age-class. The DIC pointed toward a Type IV
interaction for age groups [ 50, 60), [ 70, 80), and [ 80,+)
whereas a Type II interaction was selected for the age
group [ 60, 70). To make the different terms in all the
models comparable, a decomposition of the estimated log-
rates was computed by defining posterior spatial (ξ∗i ),
temporal (γ ∗t ) and spatio-temporal (δ∗it) patterns (see Adin
et al., [28]), so that log rit = α∗ + ξ∗i + γ ∗t + δ∗it . Note that
exp(α∗) represents the overall mortality rate for the whole
of Spain during the period 1989–2015. In order to facili-
tate interpretation of the results, a map of Spain showing



















































Fig. 2 Administrative division of Spain. Map with the administrative division of Spain showing provinces. Source: map was generated by the authors
using the library tmap [29] from the R statistical software version 3.6.2 [30]. No licenses are required to use or publish
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Figure 3 shows the map with the posterior mean
estimates of province-specific mortality rates, i.e.,
exp(α∗ + ξ∗i ). Posterior exceedance probabilities
of this province-specific rate being greater than
the overall Spanish rate have also been computed
(see Fig. 4).
The estimated spatial pattern draws attention to
Asturias as a high ovarian cancer mortality rate province
for all age groups. In the age group [50,60), the high-
est spatial rates are found in the northwestern provinces
(Asturias, Lugo, and La Coruña) but also in Vizcaya and
Huesca (over 16 cases per 100,000 women). In age group
[60,70) the regions with the highest estimated rates are
Asturias, the Balearic Islands, and Valencia (with an esti-
mated rate of over 24 cases per 100, 000 women). In the
third age group ([70,80)), the highest rates are located in
the central-northern areas (with Salamanca and Asturias
leading the ranking), and in the Canary Islands (Tenerife
province) (all of themwithmore than 33 cases per 100,000
women). The oldest age group ([80,+)) exhibits high rate
areas in Asturias, Barcelona, Gerona, and Guadalajara,
with a rate of over 35 cases per 100,000 women. All of
these high-rate provinces have a rate significantly higher
than the overall Spanish rate in their respective age groups
(see Fig. 4).
In general, northern Spain has greater ovarian cancer
mortality rates compared to the southern regions. The
lowest rates are found in Guipúzcoa for age groups [50,60)
and [60, 70), and in Almería for age groups [70,80) and
[80, +). The northwestern province of La Coruña shows




















Fig. 3 Province-specific mortality rates’ estimates by age-groups. Posterior mean estimates of province-specific mortality rates exp(α∗ + ξ∗i ).
Source: maps were generated by the authors using the library tmap [29] from the R statistical software version 3.6.2 [30]. No licenses are required to
use or publish
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Fig. 4 Province-specific posterior exceedance probabilities by age-groups. Posterior exceedance probabilities of each province in comparison with
the Spanish overall rate P(exp(α∗ + ξ∗i ) > exp(α∗)|O). Source: maps were generated by the authors using the library tmap [29] from the R
statistical software version 3.6.2 [30]. No licenses are required to use or publish
a surprising behaviour, with high rates in the age group
[50,60) but one of the lowest rates in the age group [70,80).
The estimated global temporal pattern exp(α∗ + γ ∗t ) is
visualized in Fig. 5. Rates seem to have decreased during
the last few years (from 2008 to 2013) in age group [50,
60) but have remained nearly constant in the other three
age groups, which experienced a sharp increase in rates
from 1989 up to the beginning of the twenty-first century
approximately.
Figures 6, 7, 8, and 9 display maps showing the spatio-
temporal evolution of ovarian cancer mortality rates for
each Spanish province for the period 1989–2015 (divided
into intervals of 3–4 years) for age groups [50, 60), [60, 70),
[70, 80), and [80,+), respectively. Specifically, these maps
represent the posterior mean of rit = exp(α∗ + ξ∗i + γ ∗t +
δ∗it). The correspondingmaps of probabilities (showing the
probability that a particular rate in a given province and
year is greater than the Spanish rate during that period)
are not shown here to conserve space. However, we have
classified a province as having a rate significantly greater
than the Spanish rate if this probability is greater than 0.8.
For age group [50,60), we find that the mortality rate
for the period 1989–1999 was highest in the northeastern
region, with the province of Huesca having a significant
rate that lasted until 2008. In the latter years of the period
studied, only Asturias showed a significant rate. Within
this age group, the percentage of the rate’s variability
explained by the spatio-temporal term was 29.4%, imply-
ing that the specific temporal evolution of each province
is rather high in this age group.
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Fig. 5 Temporal trends’ estimates by age-groups for the whole of Spain. Posterior mean estimates of year-specific mortality rates (exp(α∗ + γ ∗t ))










Fig. 6Mortality rates’ estimates for age group [ 50, 60). Posterior mean estimates of mortality rates rit for age group [ 50, 60). Source: maps were
generated by the authors using the library tmap [29] from the R statistical software version 3.6.2 [30]. No licenses are required to use or publish










Fig. 7Mortality rates’ estimates for age group [ 60, 70). Posterior mean estimates of mortality rates rit for age group [ 60, 70). Source: maps were










Fig. 8Mortality rates’ estimates for age group [ 70, 80). Posterior mean estimates of mortality rates rit for age group [ 70, 80). Source: maps were
generated by the authors using the library tmap [29] from the R statistical software version 3.6.2 [30]. No licenses are required to use or publish










Fig. 9Mortality rates’ estimates for age group [ 80,+). Posterior mean estimates of mortality rates rit for age group [ 80,+). Source: maps were
generated by the authors using the library tmap [29] from the R statistical software version 3.6.2 [30]. No licenses are required to use or publish
In age group 2 ([60, 70)), rates exhibit a greater vari-
ability among provinces (between 15 cases per 100,000
women and about 29 cases per 100,000 women). The
highest rates occurred in the late 1990s and early 2000s,
mainly in the northern half of Spain and in the Balearic
Islands. Asturias, Lugo, Salamanca, Valladolid, Huesca,
Teruel, Gerona, and the Balearic islands show significantly
high rates at the end of the period.
For women between 70 and 80 years of age, the low-
est rates are found at the beginning of the study period,
with significantly low rates. The highest significant rates
are located mainly in the northern and western parts of
Spain and in the Canary and Balearic islands in the period
2005–2015. The provinces with the lowest rates at the end
of the period are Gerona and Madrid.
Women over 80 years of age show significantly low rates
between 1989–1996. Again, Asturias shows the highest
mortality rate at the end of the period. Some provinces
located in southern Spain, mainly along the coastline,
show significantly low rates.
The temporal evolution of the rates for some selected
provinces are plotted in Fig. 10. The colors used in the
bands are associated to the posterior exceedance prob-
abilities of each province at year t, in comparison with
the temporal pattern for the whole of Spain in that year,
namely P(rit > α∗ + γ ∗t |O). In the case of Barcelona,
the probability that the mortality rate lies above the Span-
ish rate reaches a maximum between 1989–1996 for age
groups [50, 60) and [60,70) and between 1989–2003 for
age groups [70,80) and [80, +). Madrid behaves similar to
Spain in all age groups. In Asturias, the probability is quite
high for all age groups, with a significant rising trend for
age group [70,80) from 2002 onwards. La Coruña shows
significantly low rates during the whole study period for
the age group [70,80), whereas this province’s behaviour
for women over 80 years of age is similar to the Spanish
rate.
Discussion
The ovaries are one of the cancer sites where known
risk factors are not enough to explain all the cases, and
thus spatio-temporal analyses provide additional impor-
tant information allowing for the examination of the
spatial, temporal, and spatio-temporal mortality patterns.
As the age groups are not equally affected by ovar-
ian cancer mortality, it is necessary not just to stan-
dardize by age, but also to analyze the different age
groups.
Results show large differences in mortality among the
age groups, with higher mortality rates in the older age
groups. Indeed, the last age groups (women of more than
70 years of age) double the rate of women between 50 and
60 (more than 30 cases in the last age groups vs. 15.1 cases
per 100,000 women on average in age group [50,60)). This
can be explained by poor survival rates of gynaecological
cancers in the elderly, which in turn is influenced by late

































































































































Fig. 10 Temporal evolution of ovarian cancer mortality rates’ estimates for some selected provinces: Barcelona, Madrid, Asturias and La Coruña.
Temporal evolutions of the posterior mean estimates of mortality rates rit for some selected provinces and 95% two-sided credible intervals for age
groups [ 50, 60) (first row), [ 60, 70) (second row), [ 70, 80) (third row) and [ 80,+) (fourth row). The colors used in the bands are associated to the
posterior exceedance probabilities of each province in time t in comparison with the temporal pattern of Spain, that is, P(rit > exp(α∗ + γ ∗t )|O),
represented with a red line in the graphs
diagnoses and the failure of treatments due to comorbidity
[31, 32].
The global temporal trends (by age group) reveal that
the evolution of ovarian cancer over the whole of Spain
has remained nearly constant since the early 2000s, par-
ticularly for women aged 60 years or more, after a sharp
increase during the period 1989–2002 (approximately).
The stabilization of the rates may be due to an increased
concern among women regarding their personal health (in
particular among older women) that led them to be tested
more frequently, access to better information via mass
media and the internet, and the increasing effectiveness of
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cancer treatments. In the nineties, access to information
via the internet was more limited and health care was pos-
sibly less advanced, which could explain in part the sharp
increase in mortality rates in the first half of the period.
Mortality in women between 50 and 60 years of age shows
a slight decrease since 2008 until nearly 2013, although
this decrease does not seem to be significant with respect
to the average mortality in this age group. It seems that
in fact, during the last two years of the study period, rates
are starting to rise slightly, but once again, this trend is not
significant as yet.
The global geographical patterns show, in general, that
the North has higher rates than the South, a situation sim-
ilar to that observed overall in Europe [3]. The variability
observed in all age groups between northern and southern
Spain remains unknown, although in general, women in
the South are prone to marry earlier and have more chil-
dren on average [33]. Interestingly, Asturias, the province
with the highest rates in all age groups, is one of the
Spanish provinces with the lowest average number of chil-
dren. The differences observed between the North and the
South could also be explained taking into account the rela-
tionship between exposure to sunlight (pro-vitamin D)
and ovarian cancer. Although Spain is in general a sunny
country, there is a great variability between the North
and South in terms of average daily hours of sunlight. For
example, Bilbao in the north receives about 1500 hours
of sunlight per year while Sevilla in the south receives
3800 [34]. Thus, the observed increasing trend with lat-
itude might be at least partly explained by a cumulative
exposure to sunlight.
Heterogeneity among the provinces regarding ovarian
cancer mortality rates can be elucidated at least in part
by a heterogeneous distribution of other risk factors.
There are differences among provinces in the age at which
women have their first period (menarche), the average
age of first childbirth, and the total number of children
[35–37]. The average fecundity rate in Spain has been
markedly declining; in particular, the areas registering the
lowest fertility rates were the Basque Country, Asturias,
Navarre, and Aragón [19, 36]. We should also point out
that the age of first birthing is closely related to socioe-
conomic development, and is steadily increasing. Navarre
and the Basque Country are the regions of Spain where
women delayed childbearing the longest [37]. Addition-
ally, hormonal replacement therapy has proven to have an
important influence on the appearance of ovarian cancer
in postmenopausal women [38–41]. However, its use in
Spain has been very limited [42].
Another risk factor is the presence of a family history of
the disease [43]. Hereditary ovarian cancer syndrome pre-
senting a mutation in BRCA genes is important. Between
6–15% of ovarian cancer cases are linked to BCRA muta-
tion. Women who are carriers of the BCRA1 mutation
have a 39% chance of suffering ovarian cancer before age
70 [44]. In Spain, the accumulated risk of developing ovar-
ian cancer before age 70 has been estimated at 22% (95%
CI, 0–40%) in carriers of a mutation in BCRA1 and 18%
(95% CI, 0–35%) in carriers of a mutation in BRCA2 [44].
The prevalence of BRCA1 and BRCA2 mutation in Spain
is heterogeneous and varies according to geographical ori-
gin.Moreover, Blay et al. [45], showed that the BRCA1 and
BRCA2 spectrum of mutations in Asturias was largely dif-
ferent from other areas of Spain. This could also explain
in part the high mortality rates found in this province.
Diez et al. [46], studying a large group of Spanish patients,
showed that there is only a slight difference between
the percentages of deleterious mutations in BRCA1 and
BRCA2 genes (53% and 47%, respectively). However, some
variation due to geographic origin is present, with a higher
proportion of BRCA1 in families from the northwestern
part of Spain. According to Vega et al. [47], the differences
found in Galicia could be due to founder effects.
Ovarian cancer is also linked to lifestyle habits, tobacco
and alcohol consumption. The smoking habit is a risk
factor for epithelial ovarian cancer with an odds ratio of
2.98 (95% CI [ 1.15 − 7.73]) [12]. Differences in alcohol
and tobacco consumption can be found among Spanish
provinces [48].
All in all, to better understand the etiology of the dis-
ease and to better determine the effect of risk factors on
the Spanish female population, it would have been help-
ful to have the medical and workplace histories of all the
women participating in this study. This is the main lim-
itation of the current work. On the other hand, as there
is a lack of scientific studies analyzing the association
between ovarian cancer mortality rates and risk factors
in the domains analyzed here (age groups, provinces, and
years), spatio-temporal analyses by age groups are essen-
tial to discover inequalities in ovarian cancer mortality, to
detect provinces with high risks in each age group, and to
keep track of how the rates are evolving with time.
Conclusions
Differences in ovarian cancer mortality exist among
the Spanish provinces, years, and age groups. As the
exact causes of ovarian cancer remain unknown, spatio-
temporal analyses by age groups are very useful to look for
potential risk factors associated to the observed geograph-
ical patterns and to allocate funds among Spanish regions.
For future clinical and epidemiological practice, we rec-
ommend to follow-up women over 60 years as the mor-
tality rates remain constant since 2002. High-mortality
provinces should also be monitored to look more closely
for specific risk factors. Some risk factors for ovarian can-
cer, like getting old or having a family history, cannot be
changed. However, womenmay slightly decrease their risk
by avoiding other risk factors, for example, maintaining
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a healthy weight, avoiding tobacco and alcohol consump-
tion or not receiving hormone replacement therapy after
menopause.
Abbreviations
AEI: Spanish Research Agency; BRCA: Breast Cancer; DIC: Deviance Information
Criterion; UE: European Union; INLA: Integrated Nested Laplace
Approximations; GMRF: Gaussian Random Markov Field; SSTCDapp: Spatial
and Spatio-Temporal Count Data Application; UK: United Kingdom
Acknowledgements
We acknowledge the Spanish Statistical Institute for providing the data.
Authors’ contributions
Study conception and design: MDU, PCT Acquisition of the data: MDU, AA
Analysis of the data: MDU, PCT, AA Interpretation of the data: MDU, AA, PCT
Writing the article: PCT, MDU Critical revision of the article: All authors
approved the final manuscript and the decision to submit the manuscript.
Funding
This research has been supported by the Spanish Ministry of Science and
Innovation (project MTM 2017-82553-R (AEI/FEDER, UE). The content of this
paper is solely the responsibility of the authors and does not represent the
official views of the Spanish Ministry of Science and Innovation.
Availability of data andmaterial
Data have been provided by the Spanish Statistical Institute at municipality
level (under a contract) and aggregated later. Up on reasonable request, the
corresponding author will make the datasets available. Mortality data from
cancer and other causes from 1975 by sex and province is available in the
Interactive Epidemiological Information System (ARIADNA, http://ariadna.cne.
isciii.es/evindex.html) of the Spanish National Center for Epidemiology.





The authors declare that they have no competing interests.
Received: 14 January 2020 Accepted: 15 July 2020
References
1. Brüggmann D, Pulch K, Klingelhöfer D, Pearce C, Groneberg D. Ovarian
cancer: density equalizing mapping of the global research architecture.
Int J Health Geogr. 2017;16(1):3.
2. Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A. Global cancer
statistics 2018: Globocan estimates of incidence and mortality worldwide
for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
3. National Institute for Health and Care Excellence (NICE). Ovarian Cancer:
the Recognition and Initial Management of Ovarian Cancer. https://www.
nice.org.uk/guidance/cg122/resources/ovarian-cancer-recognition-and-
initial-management-pdf-35109446543557. Accessed 05 Jan 2020.
4. dos Santos Silva I, Beral V. Socioeconomic differences in reproductive
behaviour. IARC Sci Publ. 1997;138:285–308.
5. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo
M, Parkin DM, Forman D, Bray F. GLOBOCAN 2012 v1.0, cancer incidence
and mortality worldwide: IARC cancer base no. 11 [Internet]. Lyon:
International Agency for Research on Cancer; 2013. Available from: http://
globocan.iarc.fr. Accessed 05 Jan 2020.
6. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh J,
Comber Hea. Cancer incidence and mortality patterns in Europe:
estimates for 40 countries in 2012,. Eur J Cancer. 2013;49(6):1374–403.
7. Forman D, Bray F, Brewster DH, Gombe Mbalawa C, Kohler B, Piñeros
M, Steliarova-Foucher E, Swaminathan R, Ferlay J. Cancer Incidence in
Five Continents, Vol. X . IARC Scientific Publication No. 164, 2014. 2013.
Available from: http://publications.iarc.fr/_publications/media/
download/3743/e886b2754a75a0f70e190e9b56e5346047319c17.pdf.
Accessed 05 Jan 2020.
8. Ledermann J, Raja F, Fotopoulou C, Gonzalez-Martin A, Colombo N, C
S. European Society for Medical Oncology (ESMO) Guidelines Working
Group. Newly diagnosed and relapsed epithelial ovarian carcinoma:
ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up,.
Ann Oncol. 2013;24(6):24–32.
9. Coleman M, Gatta G, Verdecchia A, Esteve J, Sant M, Storm H, Allemani
C, Ciccolallo L, Santaquilani M, Berrino F. EUROCARE-3 summary: cancer
survival in Europe at the end of the 20th century,. Ann Oncol. 2003;14(5):
128–49.
10. Bouchardy C, Rapiti E, Blagojevic S, Vlastos A, Vlastos G. Older female
cancer patients: importance, causes, and consequences of under
treatment. J Clin Oncol. 2007;25(14):1858–69.
11. Meindl A, Ditsch N, Kast K, Rhiem K, Schmutzler R. Hereditary breast and
ovarian cancer: new genes, new treatments, new concepts. Deutsches
Ärzteblatt Int. 2011;108:323–30.
12. Solano S, Maldonado E, Ibarrola E. Asociación entre el cancer de ovario
de tipo epitelial y el tabaquismo,. Anales Médicos. 2005;50:169–71.
13. International Agency for Research on Cancer. Arsenic, Metals , Fibres, and
Dusts: IARC Monographs on the Evaluation of Carcinogenic Risks to
Humans, Volume 100C,. Lyon, France: International Agency for Research
on Cancer; 2012. ISBN: 978-91-637-4473-0.
14. Marinaccio A, Corfiati M, Binazzi A, Di Marzio D, Scarselli A, Ferrante P,
Mensi C. The epidemiology of malignant mesothelioma in women:
gender differences and modalities of asbestos exposure,. Occup Environ
Med. 2018;75(4):254–62.
15. Dovnik A, Dovnik F. Vitamin D and Ovarian Cancer: Systematic Review of
the Literature with a Focus on Molecular Mechanisms. Cells. 2020;9:335.
16. Wentzensen N, Poole E, Trabert B, White E, Arslan A, Patel A, Setiawan
V. Ovarian Cancer Risk Factors by Histologic Subtype: An Analysis From
the Ovarian Cancer Cohort Consortium,. J Clin Oncol. 2016;34:2888–98.
17. De Angelis R, Sant M, Coleman M, Francisci S, Baili P, Pierannunzio D,
Trama A, Visser O, Brenner H, Ardanaz E, Bielska-Lasota M, Engholm G,
Nennecke A, Siesling S, Berrino F, Capocaccia R. EUROCARE-5 Working
Group. Cancer survival in Europe 1999-2007 by country and age: results of
EUROCARE–5-a population-based study,. Lancet Oncol. 2014;15(1):23–34.
18. Instituto Nacional de Estadística (INE). Estadística de Defunciones 2016.
http://www.ine.es/prensa/edcm_2016.pdf. Accessed 05 Jan 2020.
19. CabanesA, Vidal E, Perez-Gomez B, Aragones N, López-Abente G, PollanM.
Age-specific breast, uterine and ovarian cancer mortality trends in Spain:
Changes from 1980 to 2006,. Cancer Epidemiology. 2009;33:169–175.
20. International Statistical Classification of Diseases and Related Health
Problems (10th Revision). https://icd.who.int/browse10/2016/en.
Accessed 05 Jan 2020.
21. Ugarte M, Adin A, Goicoa T, Militino A. On fitting spatio-temporal
disease mapping models using approximate Bayesian inference,. Stat
Methods Med Res. 2014;23:507–30.
22. Rue H, Held L. Gaussian Markov Random Fields: Theory and Applications,.
Boca Raton, FL: Chapman and Hall/CRC; 2005.
23. Rue H, Martino S, Chopin N. Approximate Bayesian inference for latent
Gaussian models by using integrated nested Laplace approximations,. J R
Stat Soc Ser B (Statistical Methodology). 2009;71(2):319–92.
24. Leroux B, Lei X, Breslow N. Estimation of disease rates in small areas: A
new mixed model for spatial dependence. In: Halloran M, Berry D,
editors. Statistical Models in Epidemiology, the Environment, and Clinical
Trials. New York: Springer; 1999. p. 179–91.
25. Knorr-Held L. Bayesian modelling of inseparable space-time variation in
disease risk. Stat Med. 2000;19:2555–67.
26. Adin A, Goicoa T, Ugarte M. Online relative risks/rates estimation in
spatial and spatio-temporal disease mapping. Comput Methods
Programs Biomed. 2019;172:103–16.
27. Spiegelhalter D, Best N, Carlin B, Van Der Linde A. J R Stat Soc Ser B
(Statistical Methodology). 2002;64(4):583–639.
28. Adin A, Martínez-Beneito M, Botella-Rocamora P, Goicoa T, Ugarte M.
Smoothing and high risk areas detection in space-time disease mapping:
a comparison of P-splines, autoregressive, and moving average models,.
Stoch Env Res Risk A. 2017;31(2):403–15.
29. Tennekes M. tmap: Thematic maps in R. J Stat Softw. 2018;84(6):1–39.
Trandafir et al. BMC Public Health         (2020) 20:1244 Page 13 of 13
30. R Core Team. R: A Language and Environment for Statistical Computing. R
Foundation for Statistical Computing: R Foundation for Statistical
Computing; 2019. https://www.R-project.org/.
31. Sant M, Aareleid T, Berrino F, Bielska Lasota M, Carli P, Faivre J,
Grosclaude P, Hedelin G, Matsuda T, Moller H, Moller T, Verdecchia A,
Capocaccia R, Gatta G, Micheli A, Santaquilani M, Roazzi P, Lisi D,
Group E. EUROCARE-3: survival of cancer patients diagnosed 1990-94
results and commentary,. Ann Oncol. 2003;14(5):61–118.
32. Sant M, Chirlaque Lopez M, Agresti R, Sanchez Perez M, Holleczek B,
Bielska-Lasota M, Dimitrova N, Innos K, Katalinic A, Langseth H,
Larranaga N, Rossi S, Siesling S, Minicozzi P. Survival of women with
cancers of breast and genital organs in Europe 1999-2007: Results of the
EUROCARE-5 study. Eur J Cancer. 2015;51:2191–205.
33. España en Cifras 2015. Instituto Nacional de Estadística. Madrid. https://
www.ine.es/prodyser/espa_cifras/2015/index.html. Accessed 05 Jan 2020.
34. Climatología. Instituto Nacional de Estadística. Madrid. https://www.ine.
es/daco/daco42/bme/c19.pdf. Accessed 15 May 2020.
35. Pike M. Age-related factors in cancers of the breast, ovary, and
endometrium. J Chronic Dis. 1987;40(2):595–695.
36. Cabanes A, Ascunce N, Vidal E, Ederra M, Barcos A, Erdozain N, Lope V,
Pollan M. Decline in age at menarche among Spanish women born from
1925 to 1962,. BMC Public Health. 2009;9:449.
37. Arroyo A. Tendencias Demográficas Durante el Siglo XX en España. In:
Arroyo A, editor. Madrid: INE; 2004. p. 119–62.
38. Beral V, Bull D, Green J, Reeves G. Ovarian cancer and hormone
replacement therapy in the Million Women Study. Lancet. 2007;369:
1703–842.
39. Beral V, Gaitskell K, Hermon C, Moser K, Reeves G, Peto R. The
Collaborative Group on Epidemiological Studies of Ovarian Cancer,
Menopausal hormone use and ovarian cancer risk: individual participant
meta-analysis of 52 epidemiological studies. Lancet. 2015;385:1835–42.
40. Gompel A, Burger H. A commentary on a recent update of the ovarian
cancer risk attributable to menopausal hormone therapy. Climacteric.
2015;18(3):376–8.
41. Friisa S, Kesminiene A, Espina C, Auvinen A, Straif K, Schüz J. European
Code against Cancer 4th Edition: Medical exposures, including hormone
therapy, and cancer,. Cancer Epidemiology. 2015;39(1):107–19.
42. Schneider H. Cross-national study of women’s use of hormone
replacement therapy (HRT) in Europe,. Int J Fertil Women’ s Med.
1997;42(2):365–75.
43. Antoniou A, Pharoah P, Narod S, Risch H, Eyfjord J, Hopper J, Loman N,
Olsson H, Johannsson O, Borg A, et al. Average risks of breast and ovarian
cancer associated with brca1 or brca2 mutations detected in case series
unselected for family history: a combined analysis of 22 studies. Am J
Hum Genet. 2003;72(5):1117–30.
44. Milne R, Osorio A, Cajal T, Vega A, Llort G, de la Hoya M, Díez O, Alonso
M, Lazaro C, Blanco I, Sánchez-de- Abajo A, Caldés T, Blanco A, Graña B,
Durán M, Velasco E, Chirivella I, Cardeñosa E, Tejada M, Beristain E,
Miramar M, Calvo M, Martínez E, Guillén C, Salazar R, San Román C,
Antoniou A, Urioste M, Benítez J. The average cumulative risks of breast
and ovarian cancer for carriers of mutations in BRCA1 and BRCA2
attending genetic counseling units in Spain,. Clin Cancer Res. 2008;14(9):
2861–9.
45. Blay P, Santamaría I, Pitiot A, Luque M, Alvarado M, Lastra A, Fernández
Y, Paredes A, Freije J, Balbín M. Mutational analysis of BRCA1 and BRCA2
in hereditary breast and ovarian cancer families from Asturias (Northern
Spain). BMC Cancer. 2013;13:243.
46. Diez O, Osorio A, Duran M, Martinez-Ferrandis J, de la Hoya M, Salazar R,
Vega A, Campos B, Rodriguez-Lopez R, Velasco Eea. Analysis of BRCA1
and BRCA2 genes in Spanish breast/ovarian cancer patients: a high
proportion of mutations unique to Spain and evidence of founder
effects,. Hum Mutat. 2003;22(4):3014–312.
47. Vega A, Torres M, Martinez J, Ruiz-Ponte C, Barros F, Carracedo A.
Analysis of BRCA1 and BRCA2 in breast and breast/ovarian cancer families
shows population substructure in the Iberian peninsula. Ann Hum Genet.
2002;66:29–36.
48. Encuesta de Salud. Instituto Nacional de Estadística. Madrid. https://www.
ine.es/dynt3/inebase/es/index.htm?type=pcaxis&path=/t15/p419/
a2017/p03/&file=pcaxis. Accessed 15 May 2020.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
